312 related articles for article (PubMed ID: 12189361)
1. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
3. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.
Jung D; Dorr A
J Clin Pharmacol; 1999 Aug; 39(8):800-4. PubMed ID: 10434231
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
[TBL] [Abstract][Full Text] [Related]
6. Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl.
Burri M; Wiltshire H; Kahlert C; Wouters G; Rudin C
Pediatr Infect Dis J; 2004 Mar; 23(3):263-6. PubMed ID: 15014306
[TBL] [Abstract][Full Text] [Related]
7. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
8. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation.
Pescovitz MD; Jain A; Robson R; Mulgaonkar S; Freeman R; Bouw MR
Transplant Proc; 2007 Dec; 39(10):3111-6. PubMed ID: 18089334
[TBL] [Abstract][Full Text] [Related]
9. New AUC-based method to estimate drug fraction removed by hemodialysis.
Czock D; Rasche FM
Kidney Blood Press Res; 2004; 27(3):172-6. PubMed ID: 15256813
[TBL] [Abstract][Full Text] [Related]
10. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
Razonable RR; Paya CV
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
[TBL] [Abstract][Full Text] [Related]
11. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.
Acosta EP; Brundage RC; King JR; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud G; Whitley R; Kimberlin DW;
Clin Pharmacol Ther; 2007 Jun; 81(6):867-72. PubMed ID: 17392728
[TBL] [Abstract][Full Text] [Related]
12. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients.
Pescovitz MD
Transpl Infect Dis; 1999; 1 Suppl 1():31-4. PubMed ID: 11565585
[TBL] [Abstract][Full Text] [Related]
13. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
Yu MA; Park JM
Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
[TBL] [Abstract][Full Text] [Related]
14. [Valganciclovir. Oral treatment of Cytomegalovirus infections].
Kroes AC
Ned Tijdschr Geneeskd; 2004 Jun; 148(25):1236-8. PubMed ID: 15301386
[TBL] [Abstract][Full Text] [Related]
15. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
Lalezari J; Lindley J; Walmsley S; Kuppermann B; Fisher M; Friedberg D; Lalonde R; Matheron S; Nieto L; Torriani FJ; Van Syoc R; Sutton MA; Buhles W; Stempien MJ;
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):392-400. PubMed ID: 12138345
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.
Kimberlin DW; Acosta EP; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud GA; Lakeman FD; Whitley RJ;
J Infect Dis; 2008 Mar; 197(6):836-45. PubMed ID: 18279073
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ganciclovir and valganciclovir in the adult horse.
Carmichael RJ; Whitfield C; Maxwell LK
J Vet Pharmacol Ther; 2013 Oct; 36(5):441-9. PubMed ID: 23301502
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
[TBL] [Abstract][Full Text] [Related]
20. Valganciclovir.
Curran M; Noble S
Drugs; 2001; 61(8):1145-50 ; discussion 1151-2. PubMed ID: 11465875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
